Table 2.
KER certainties (probability distribution means and standard deviations)
| AOP | KER | Mean | Std |
|---|---|---|---|
| SULT1E1 inhibition | KER1: from SULT1E1 inhibition to increased E2 availability in the uterus | 0.61 | 0.06 |
| KER2: from increased E2 availability in the uterus to ER activation | 0.75 | 0.06 | |
| Reduced availability of GnRH leading to uterine adenocarcinoma via increased estrogen availability at the target organ level | KER1: reduced GnRH availability pulsatory release leads to decrease/delayed LH surge | 0.82 | 0.04 |
| KER2: reduced LH surge leads to delayed ovulation | 0.82 | 0.05 | |
| KER3: delayed ovulation leads to estrogen dominance | 0.68 | 0.04 | |
| ER activation led to uterine adenocarcinoma via epigenetic modulation | KER1: era activation leading to epigenetic modulation | 0.4 | 0.11 |
| KER2: epigenetic modulation leading to altered expression of factors ruling proliferation | 0.62 | 0.1 | |
| KER3: expression of factors ruling proliferation leading to an increased proliferation (hyperplasia) | 0.84 | 0.05 | |
| KER4: increased proliferation leads to genetic instability (accumulation of mutations) | 0.54 | 0.06 | |
| KER5: genetic instability (accumulation of mutations) leads to uterine adenocarcinoma | 0.4 | 0.08 |